BofA initiated coverage of Ligand (LGND) with a Buy rating and $244 price target Citing a portfolio of more than 100 high-value commercial and development assets, increasing needs for flexible, non-dilutive capital in the industry and a lean cost structure, the analyst contends that the biopharma royalty firm can continue to deliver on its “aggressive earnings targets.”
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, alerts, and much more.
